Kristine Griffett, MS, PhD

St. Louis College of Pharmacy (STLCOP)

My current research focuses on nuclear hormone receptor physiology and pharmacology for developing targeted therapeutics for cardio-metabolic diseases. Current and previous funded work focuses on targeting the Liver X Receptors with novel tissue-specific compounds to treat fatty liver diseases (NAFLD and NASH) and atherosclerosis. Other research projects are identifying role of the nuclear receptor REV-ERB in the development of fibrosis and inflammatory response during the progression of liver disease, elucidating the natural ligands of orphan receptors involved in proliferation and stemness in glioblastoma, and characterizing novel scaffolds of drugs targeting LXR for Alzheimer’s Disease, Inflammation, and COPD. Dr. Griffett is currently funded by the American Heart Association.